216959-91-0

Basic information

• Product Name: 4-(Pyrimidin-5-yl)benzoic acid
• Synonyms: 4-(5-PYRIMIDINYL)BENZOIC ACID;4-PYRIMIDIN-5-YL-BENZOIC ACID;AKOS BAR-0646;4-Pyrimidin-5-yl-benzoicacid95%;4-(2-(Methylthio)pyrimidin-5-yl)benzoic acid;4-(2,4-Dimethoxypyrimidin-5-yl)benzoic acid;4-(2-Chloropyrimidin-5-yl)benzoic acid;4-(2-Methoxypyrimidin-5-yl)benzoic acid
• CAS NO: 216959-91-0
• Molecular Formula: C₁₁H₈N₂O₂
• Molecular Weight: 200.19
• Mol File: 216959-91-0.mol

Chemical Properties

• Melting Point: 316-317 ºC
• Boiling Point: 419.5 °C at 760 mmHg
• Flash Point: 207.5 °C
• Appearance: /
• Density: 1.303 g/cm³
• Vapor Pressure: 8.69E-08mmHg at 25°C
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 3.81±0.10(Predicted)
• CAS DataBase Reference: 4-(Pyrimidin-5-yl)benzoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(Pyrimidin-5-yl)benzoic acid(216959-91-0)
• EPA Substance Registry System: 4-(Pyrimidin-5-yl)benzoic acid(216959-91-0)

Safety Data

• Hazard Codes: Xn
• Statements: 22-36/37/38
• Safety Statements: 22-26-36/37/39
• Hazardous Substances Data: 216959-91-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
4-(Pyrimidin-5-yl)benzoic acid is used as a building block for the synthesis of various pharmaceutical drugs due to its unique structure and reactivity. It can contribute to the development of new therapeutic agents with potential applications in treating a range of diseases.
Used in Organic Synthesis:
In the field of organic synthesis, 4-(Pyrimidin-5-yl)benzoic acid is utilized as a key intermediate for the creation of diverse organic compounds. Its presence in synthetic pathways can lead to the production of specialty chemicals and materials with specific properties for various applications.
Used in Medicinal Chemistry Research:
4-(Pyrimidin-5-yl)benzoic acid serves as an interesting target for further research in medicinal chemistry. Its unique structure allows for exploration of its potential interactions with biological targets, which could lead to the discovery of new drugs or drug candidates with improved efficacy and selectivity.
Used in Chemical Synthesis Development:
4-(Pyrimidin-5-yl)benzoic acid is also used in the development of new chemical synthesis methods. Its reactivity and structural features can be leveraged to design novel synthetic routes, potentially leading to more efficient and sustainable chemical production processes.

InChI:InChI=1/C11H8N2O2/c14-11(15)9-3-1-8(2-4-9)10-5-12-7-13-6-10/h1-7H,(H,14,15)/p-1

Upstream product

• 4595-59-9 5-bromopyrimidine 
• 14047-29-1 4-carboxyphenylboronic acid 
• 586-76-5 4-Bromobenzoic acid 
• 619-42-1 4-methoxycarbonylphenyl bromide 
• 109299-78-7 pyrimidine 5-boronic acid 
• 198084-12-7 4-(pyrimidin-5-yl)benzaldehyde 
• 82525-18-6 4-(pyrimidin-5-yl)benzoic acid ethyl ester 
• 87199-17-5 4-formylphenylboronic acid, 

Downstream Products

• 1441811-05-7 C₄₁H₄₀N₄O₅ 
• 1354353-53-9 N-(3-fluoro-4-(2-methylpyridin-4-yl)benzyl)-4-(pyrimidin-5-yl)benzamide 

Relevant articles and documents

Supramolecular Isomers of Metal-Organic Frameworks Derived from a Partially Flexible Ligand with Distinct Binding Motifs

Three novel metal-organic frameworks (MOFs) were isolated upon reacting heterofunctional ligand 4-(pyrimidin-5-yl)benzoic acid (4,5-pmbc) with mixed valence Cu(I,II) under solvothermal conditions. X-ray crystal structural analysis reveals that the first c

Design, synthesis and stepwise optimization of nitrile-based inhibitors of cathepsins B and L

Human cathepsin B (CatB) is an important biological target in cancer therapy. In this work, we performed a knowledge-based design approach and the synthesis of a new set of 19 peptide-like nitrile-based cathepsin inhibitors. Reported compounds were assayed against a panel of human cysteine proteases: CatB, CatL, CatK, and CatS. Three compounds (7h, 7i, and 7j) displayed nanomolar inhibition of CatB and selectivity over CatK and CatL. The selectivity was achieved by using the combination of a para biphenyl ring at P3, halogenated phenylalanine in P2 and Thr-O-Bz group at P1. Likewise, compounds 7i and 7j showed selective CatB inhibition among the panel of enzymes studied. We have also described a successful example of bioisosteric replacement of the amide bond for a sulfonamide one [7e → 6b], where we observed an increase in affinity and selectivity for CatB while lowering the compound lipophilicity (ilogP). Our knowledge-based design approach and the respective structure–activity relationships provide insights into the specific ligand-target interactions for therapeutically relevant cathepsins.

KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE

Disclosed herein are new compounds and compositions and their application as pharmaceuticals for the treatment of diseases. Methods of inhibition of KDM1A, methods of increasing gamma globin gene expression, and methods to induce differentiation of cancer cells in a human or animal subject are also provided for the treatment of diseases such as acute myelogenous leukemia.

PYRROLIDINE OR THIAZOLIDINE CARBOXYLIC ACID DERIVATIVES, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING METABOLIC DISORDERSAS AS AGONISTS OF G- PROTEIN COUPLED RECEPTOR 43 (GPR43)

The present invention is directed to novel compounds of formula (I) and their use in treating and/or preventing metabolic diseases.

Structural modifications of salicylates: Inhibitors of human CD81-receptor HCV-E2 interaction

Starting point of the present paper was the result of a virtual screening using the open conformation of the large extracellular loop (LEL) of the CD81-receptor (crystal structure: PDB-ID: 1G8Q). After benzyl salicylate had been experimentally validated to be a moderate inhibitor of the CD81-LEL-HCV-E2 interaction, further optimization was performed and heterocyclic-substituted benzyl salicylate derivatives were synthesized. The compounds were tested for their ability to inhibit the interaction of a fluorescence-labeled antibody to CD81-LEL using HUH7.5 cells. No compound showed an increase concerning the inhibition of the protein-protein interaction compared to benzyl salicylate.

Pyrrolobenzodiazepine pyridine carboxamides and derivatives as follicle-stimulating hormone receptor antagonists

This invention provides pyrrolobenzodiazepine pyridine carboxamides selected from those of Formula (1), which act as follicle stimulating hormone receptor antagonists. The invention also provides pharmaceutical compositions and methods of treatment utilizing the compounds of Formulae (1) and (2).

Biarylcarboxybenzamide derivatives as potent vanilloid receptor (VR1) antagonistic ligands

Seventeen biarylcarboxybenzamide derivatives were prepared for the study of their agonistic/antagonistic activities to the vanilloid receptor (VR1) in rat DRG neurons. The replacement of the piperazine moiety of the lead compound 1 with phenyl ring showed quite enhanced antagonistic activity. Among the prepared derivatives, N-(4-tert-butylphenyl)-4-pyridine-2-yl-benzamide (2, IC 50 = 31 nM) and N-(4-tert-butylphenyl)-4-(3-methylpyridine-2-yl) benzamide (3g, IC50 = 31 nM), showed 5-fold higher antagonistic activity than 1 in 45Ca2+-influx assay.

PIPERIDINES USEFUL FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS

The invention relates to compounds which are substituted chiral or achiral derivatives of 3- or 4- aminopiperidine of the general formula (I). The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more compounds of general formula I and especially their use as inhibitors of β-secretases.

SUBSTITUTED (AMINOIMINOMETHYL OR AMINOMETHYL) BENZOHETEROARYL COMPOUNDS

This invention is directed to an (aminoiminomethyl or aminomethyl) benzoheteroaryl compound of formula I which is useful for inhibiting the activity of Factor Xa by combining said compound with a composition containing Factor Xa. The present invention is also directed to compositions containing compounds of the formula I, methods for their preparation, their use, such as in inhibiting the formation of thrombin or for treating a patient suffering from, or subject to, a disease state associated with a physiologically detrimental excess amount of thrombin.

Substituted (aminoiminomethyl or aminomethyl) dihydrobenzofurans and benzopyrans

This invention is directed to substituted (aminoiminomethyl or aminomethyl) dihydrobenzofurans and benzopyrans that inhibit Factor Xa, pharmaceutical compositions comprising these compounds and their use for inhibiting Factor Xa or treating pathological conditions in a patient that may be ameliorated by administration of such compounds. This invention is also is also directed to substituted (aminoiminomethyl or aminomethyl) dihydrobenzofurans and benzopyrans which directly inhibit both Factor Xa and Factor IIa (thrombin), to pharmaceutical compositions comprising these compounds, to intermediates useful for preparing these compounds and to a method of simultaneously directly inhibiting both Factor Xa and Factor IIa (thrombin).